Safety of PDT-Photofrin® Prior to Lung Surgery
Status: | Completed |
---|---|
Conditions: | Lung Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - 79 |
Updated: | 3/28/2019 |
Start Date: | August 14, 2017 |
End Date: | March 22, 2019 |
A Multicenter, Prospective, Open-label, Non-randomized Single-arm Clinical Study of the Safety and Tissue Response to Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Solid Lung Tumor Prior to Surgical Resection
This research study is being conducted to assess the safety of PDT in subjects with
peripherally located malignant tumors in lung parenchyma prior to surgical resection. It will
involve up to 10 sites in USA. Participation will last 4 months.
peripherally located malignant tumors in lung parenchyma prior to surgical resection. It will
involve up to 10 sites in USA. Participation will last 4 months.
Lung cancer accounts for almost one-third of cancer deaths. Cancer screening strategies have
the potential to achieve a 20% reduction in death rates. Newly developed bronchoscopic
technologies (such as navigational bronchoscopy) have been shown to enable physicians to
safely reach lesions in peripheral regions of the lung and obtain diagnosis. This new
technology may now potentially offer bronchoscopic therapeutic interventions, such as
photodynamic therapy, to tumors that were previously unreachable due to their peripheral
anatomic location.
Photodynamic therapy (PDT) uses a combination of a photosensitizing drug (a drug that is
activated by light), called porfimer sodium (Photofrin®), and a light from a laser that emits
no heat. This technique works to allow the medical doctor to specifically target and destroy
abnormal or cancer cells while limiting damage to surrounding healthy tissue. The activation
of the drug is done by lightning the abnormal area using a fiber optic device (very fine
fiber [like a fishing line] that permits light transmission) inserted into a flexible tube
with a light, called bronchoscope for the lung. The light activates the porfimer sodium
concentrated in the abnormal tissue, leading to its destruction.
The purpose of this study is to assess the safety of using photodynamic therapy prior to
surgical resection of tumors located in the periphery of the lung.
the potential to achieve a 20% reduction in death rates. Newly developed bronchoscopic
technologies (such as navigational bronchoscopy) have been shown to enable physicians to
safely reach lesions in peripheral regions of the lung and obtain diagnosis. This new
technology may now potentially offer bronchoscopic therapeutic interventions, such as
photodynamic therapy, to tumors that were previously unreachable due to their peripheral
anatomic location.
Photodynamic therapy (PDT) uses a combination of a photosensitizing drug (a drug that is
activated by light), called porfimer sodium (Photofrin®), and a light from a laser that emits
no heat. This technique works to allow the medical doctor to specifically target and destroy
abnormal or cancer cells while limiting damage to surrounding healthy tissue. The activation
of the drug is done by lightning the abnormal area using a fiber optic device (very fine
fiber [like a fishing line] that permits light transmission) inserted into a flexible tube
with a light, called bronchoscope for the lung. The light activates the porfimer sodium
concentrated in the abnormal tissue, leading to its destruction.
The purpose of this study is to assess the safety of using photodynamic therapy prior to
surgical resection of tumors located in the periphery of the lung.
Inclusion Criteria:
- Male or female aged 18-79
- Diagnosed with primary or metastatic tumor < 5 cm located in peripheral lung
- Candidate for surgical resection
- Candidate for bronchoscopy
Exclusion Criteria:
- Diagnostic of small cell lung cancer or carcinoid tumors
- Primary or metastatic lung tumor located in central lung or near vertebral body
- Tumor invades a major blood vessel
- Presence of concurrent non-solid malignancy
- Tumor previously treated with radiation therapy
- Chemotherapy in the last four weeks
- Tumor treated with PDT within the last 3 months
- Abnormal blood results
We found this trial at
8
sites
600 Celebrate Life Pkwy
Atlanta, Georgia 30265
Atlanta, Georgia 30265
Principal Investigator: Rabih I Bechara, MD
Phone: 770-400-7194
Click here to add this to my saved trials

8700 Beverly Blvd # 8211
Los Angeles, California 90048
Los Angeles, California 90048
(1-800-233-2771)

Principal Investigator: Harmik J Soukiasian, MD
Phone: 310-423-8762
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials

Denver, Colorado 80210
Principal Investigator: Ali I Musani, MD
Phone: 720-848-0676
Click here to add this to my saved trials

100 Hospital Avenue
DuBois, Pennsylvania 15801
DuBois, Pennsylvania 15801
Principal Investigator: Sandeep Bansal, MD
Phone: 814-940-1212
Click here to add this to my saved trials

Elk Grove Village, Illinois 60007
Principal Investigator: Neeraj R Desai, MD
Phone: 847-230-3993
Click here to add this to my saved trials

Houston, Texas 77030
Principal Investigator: Roberto F Casal, MD
Phone: 713-745-2645
Click here to add this to my saved trials

Spokane, Washington 99204
Principal Investigator: Jiten D Patel, MD
Phone: 509-474-3823
Click here to add this to my saved trials

Click here to add this to my saved trials
